Literature DB >> 34001823

Improved 18-FDG PET/CT diagnosis of multiple myeloma diffuse disease by radiomics analysis.

Charles Mesguich1,2,3, Elif Hindie1, Baudouin Denis de Senneville3, Ghoufrane Tlili1, Jean-Baptiste Pinaquy1, Gerald Marit2, Olivier Saut3.   

Abstract

OBJECTIVES: In multiple myeloma, the diagnosis of diffuse bone marrow infiltration on 18-FDG PET/CT can be challenging. We aimed to develop a PET/CT radiomics-based model that could improve the diagnosis of multiple myeloma diffuse disease on 18-FDG PET/CT.
METHODS: We prospectively performed PET/CT and whole-body diffusion-weighted MRI in 30 newly diagnosed multiple myeloma. MRI was the reference standard for diffuse disease assessment. Twenty patients were randomly assigned to a training set and 10 to an independent test set. Visual analysis of PET/CT was performed by two nuclear medicine physicians. Spine volumes were automatically segmented, and a total of 174 Imaging Biomarker Standardisation Initiative-compliant radiomics features were extracted from PET and CT. Selection of best features was performed with random forest features importance and correlation analysis. Machine-learning algorithms were trained on the selected features with cross-validation and evaluated on the independent test set.
RESULTS: Out of the 30 patients, 18 had established diffuse disease on MRI. The sensitivity, specificity and accuracy of visual analysis were 67, 75 and 70%, respectively, with a moderate kappa coefficient of agreement of 0.6. Five radiomics features were selected. On the training set, random forest classifier reached a sensitivity, specificity and accuracy of 93, 86 and 91%, respectively, with an area under the curve of 0.90 (95% confidence interval, 0.89-0.91). On the independent test set, the model achieved an accuracy of 80%.
CONCLUSIONS: Radiomics analysis of 18-FDG PET/CT images with machine-learning overcame the limitations of visual analysis, providing a highly accurate and more reliable diagnosis of diffuse bone marrow infiltration in multiple myeloma patients.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34001823     DOI: 10.1097/MNM.0000000000001437

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  3 in total

Review 1.  Machine Learning and Deep Learning Applications in Multiple Myeloma Diagnosis, Prognosis, and Treatment Selection.

Authors:  Alessandro Allegra; Alessandro Tonacci; Raffaele Sciaccotta; Sara Genovese; Caterina Musolino; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

2.  11C-Methionine PET/CT in Assessment of Multiple Myeloma Patients: Comparison to 18F-FDG PET/CT and Prognostic Value.

Authors:  Maria I Morales-Lozano; Paula Rodriguez-Otero; Lidia Sancho; Jorge M Nuñez-Cordoba; Elena Prieto; Maria Marcos-Jubilar; Juan J Rosales; Ana Alfonso; Edgar F Guillen; Jesus San-Miguel; Maria J Garcia-Velloso
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208

3.  Comparison of FDG PET/CT and Bone Marrow Biopsy Results in Patients with Diffuse Large B Cell Lymphoma with Subgroup Analysis of PET Radiomics.

Authors:  Eun Ji Han; Joo Hyun O; Hyukjin Yoon; Seunggyun Ha; Ie Ryung Yoo; Jae Won Min; Joon-Il Choi; Byung-Ock Choi; Gyeongsin Park; Han Hee Lee; Young-Woo Jeon; Gi-June Min; Seok-Goo Cho
Journal:  Diagnostics (Basel)       Date:  2022-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.